A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Olanzapine/samidorphan (Primary)
- Indications Bipolar I disorders; Psychotic disorders; Schizophrenia
- Focus Adverse reactions; Registrational
- Sponsors Alkermes plc
- 01 Aug 2019 Planned End Date changed from 1 Jan 2021 to 1 Dec 2022.
- 01 Aug 2019 Planned primary completion date changed from 1 Jan 2021 to 1 Dec 2022.
- 30 Jun 2017 New trial record